Professional Experience
Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Mr. Wong also has extensive experience with intellectual property counseling, pre-suit investigations, licensing and due diligence.
Mr. Wong currently is the Chair of the Recruiting Committee and also serves as faculty for NITA (the National Institute of Trial Advocacy).
Awards and Recognition
Ha Kung Wong is listed in Legal 500 2008 and 2009 for Patent litigation: full coverage.
Professional Activities
American Bar Association; New York Bar Association; New York Patent Law Association; American Chemical Society; New York Intellectual Property Law Association
Additional Publications
While in law school, Mr. Wong served as Managing Editor for the Journal of Legislation and published, "The Extra in Extradition: Washington v. Pang's Impact on Extraditee Standing and Implicit Waiver," 24 J.Legis 111 (1998).
Representative Matters
· AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
· Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
· UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
· GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
· UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.
Decisions
Representative Cases
UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al.
N.D. GA 2006
In re Omeprazole Patent Litigation
S.D.N.Y. 2002
Publications/Events
Publications
Conducting an IP Audit When Laws Change
New York Law Journal
May 9, 2012
Trade Secret Law Reform: Could an Amended Economic Espionage Act Overcome Inconsistencies in the Current State Law System?
Bloomberg Law Reports: Intellectual Property
January 2012
Preparing for Uncertainties in Biosimilars Litigation
Financier Worldwide
January 2011
Recent legislation impacts development of biologics
Financier Worldwide
November 2010
Obvious to Try? The Slippery Slope of Biotechnology
Bloomberg Law Reports Intellectual Property
May 10, 2010
Combine and conquer: handling biotech combination inventions in the wake of KSR
Nature Biotech
May 2009
Events
America Invents Act: The Significant Changes for Patent Prosecutors and Litigators
Lawline.com October 21, 2011
C5's 21st Forum on Biotech Patenting
C5
October 5-6, 2011
ACI's 2nd Annual Conference on Biosimilars
American Conference Institute
Fitzpatrick partners Raymond Mandra and Ha Kung Wong spoke at ACI's 2nd Annual Conference on Biosimilars
June 7-8, 2011
3rd Annual Pre-Litigation Strategy, Analysis and Preparation for Paragraph IV Disputes
The Center for Business Intelligence
October 18- 19, 2010
Assessing Small Molecule IP: Exclusivities & the Hatch-Waxman Act
lawline.com
September 15, 2010
5th Annual Pharmaceutical & Biotech Patent Litigation Strategies Conference
IQPC
Partners Scott K. Reed and Ha Kung Wong to speak at Biotech Conference in London
May 24-26th, 2010
Highlighting In-Depth Interference Practices, Patent Life Cycle Management and Litigation Tactics
IQPC's 2nd Annual Patent Strategies for the Pharma, Biotech and Medical Device Industries
July 15-16, 2008
News
Press Releases
New Partners named in January 2008
January 2, 2008